Researchers are studying whether these widely used weight-loss drugs may also be future treatments for alcohol abuse.

Novo Nordisk (NVO) plans to run studies on how its GLP-1 class of weight loss/diabetes drug can help people deal with ...

One in eight Americans is currently taking a GLP-1 to lose weight or treat a chronic condition.

Saha is senior vice president of government affairs for Premier Inc. McMullan is senior director of payment policy at Premier Inc. Today, more than 40% of adults over 60 are considered obese, fueling ...

Studies presented at Obesity Week 2025 validate the test's ability to predict weight-loss response to GLP-1 drugs like semaglutide, including in diverse patient populations and post-bariatric surgery ...

New program pairs microdoses of GLP-1 medication with Noom’s powerful behavior-change program and at-home biomarker testing ...

Ash will provide at-home biomarker testing to Noom users to provide insights into key health markers linked to chronic ...

Glucagon-like peptide-1 (GLP-1) agonists have transformed weight loss treatments. However, about half of the patients who take these drugs stop within a year because of unwanted side effects. 1,2 For ...

There is no exact known number of GLP-1 patients who say their say their sense of taste has changed since starting the ...

GLP-1 weight loss drugs are proving beneficial for people struggling with obesity and diabetes, but there is another surprising side effect coming to light.

The MarketWatch News Department was not involved in the creation of this content. Studies presented at Obesity Week 2025 validate the test's ability to predict weight-loss response to GLP-1 drugs like ...